KalVista Pharmaceuticals, Inc. (FRA:4XC1)

Germany flag Germany · Delayed Price · Currency is EUR
11.90
-0.10 (-0.83%)
At close: Dec 1, 2025
28.65%
Market Cap630.76M
Revenue (ttm)1.25M
Net Income (ttm)-177.55M
Shares Outn/a
EPS (ttm)-3.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume57
Open11.90
Previous Close12.00
Day's Range11.90 - 11.90
52-Week Range6.95 - 14.00
Betan/a
RSI62.21
Earnings DateDec 5, 2025

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Benjamin Palleiko
Employees 270
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4XC1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.